ReviewClinical, cosmetic and investigational dermatology2026
Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition often linked with metabolic dysfunction and insulin resistance. Antidiabetic medications have been explored as adjunctive therapies due to their anti-inflammatory and anti-androgenic effects. This systematic review evaluated the effectiveness and safety of antidiabetic agents in HS management. Patients and Methods: A comprehensive search was conducted in PubMed, Scopus, Web of Science, CINAHL Ultimate, and Google Scholar. Eligible studies assessed the efficacy or safety of antidiabetic drugs in HS patients. Fifteen studies, comprising 3721 participants, met inclusion criteria. Results: Metformin was the most studied drug, included in 10 studies. Several investigations showed reductions in HS lesion counts, flare frequency, and disease severity scores (Hurley stage, Sartorius score, Visual Analog Scale). Quality of life improvements, measured by the Dermatology Life Quality Index (DLQI), were observed with metformin, liraglutide, and tirzepatide. Gastrointestinal side effects were the most frequently reported, particularly with metformin. However, no severe or unexpected adverse events were linked to GLP-1 receptor agonists or SGLT2 inhibitors. Conclusion: Overall, antidiabetic medications, especially metformin and GLP-1 receptor agonists, appear beneficial for HS. They may reduce disease severity and improve quality of life while maintaining a favorable safety profile. Nevertheless, additional high-quality randomized controlled trials are urgent to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.